BBHC
XENE icon

Brown Brothers Harriman & Co’s Xenon Pharmaceuticals XENE Stock Holding History

Brown Brothers Harriman & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-294
Closed -$9K – 1429
2022
Q1 		$9K Hold
294
– – ﹤0.01% 1053
2021
Q4 		$9 Buy
+294
New +$8.79K ﹤0.01% 942

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brown Brothers Harriman & Co's XENE Position: Q2 2022 in Review

Brown Brothers Harriman & Co sold out of Xenon Pharmaceuticals (XENE) in Q2 2022, closing a stake of 294 shares — an estimated $9K sold.

Brown Brothers Harriman & Co first reported a position in XENE in Q4 2021 and held it in 2 quarters. The position peaked at $9K in Q1 2022. 151 funds tracked by Wall St. Rank hold XENE as of Q2 2022.

  • Brown Brothers Harriman & Co reported no remaining Xenon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 294 Xenon Pharmaceuticals shares in Q2 2022, an estimated $9K.
  • Brown Brothers Harriman & Co first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Brown Brothers Harriman & Co's Xenon Pharmaceuticals position peaked at $9K in Q1 2022.
  • 151 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2022, filed 11 Aug 2022.